Pharmacotherapy of major depressive disorder in adolescents
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
IMPORTANCE OF THE FIELD: At any one time, major depressive disorder (MDD) affects 4 - 6% of adolescents. When untreated, MDD leads to a high immediate and subsequent suicide risk, long-term chronicity and a poor psychosocial outcome. Whereas psychotherapy can be effective in mild depression, it seems to be less effective in moderate and severe depression. However, although the use of antidepressants increased markedly during the 1990s, in recent years it has decreased as a result of concerns regarding the emergence of suicidality during antidepressant treatment. AREAS COVERED IN THIS REVIEW: Are antidepressants truly effective? What is the relationship between different treatments for depression - psychotherapy and pharmacotherapy - alone or in combination? Can antidepressants increase the risk of suicide in some adolescents? Can antidepressants reduce suicide risk in suicidal adolescents? WHAT THE READER WILL GAIN: There is evidence that selective serotonin reuptake inhibitors (SSRIs) can improve adolescent depression better than placebo, although the magnitude of the antidepressant effect is 'small to moderate', because of a high placebo response. The SSRI with the best rate of response compared to placebo is fluoxetine. The increased risk of suicidality in adolescents, compared to adults, is weak but consistent across most studies. However, epidemiological studies do not support a relationship between use of antidepressants and suicide rate. TAKE HOME MESSAGE: A cautious and well-monitored use of antidepressant medications is a first-line treatment option in adolescents with moderate to severe depression. Low rates of remission with current treatment strategies indicate that further research in both psychotherapy and pharmacotherapy is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bridge, J. A., Iyengar, S., Salary, C. B., Barbe, R. P., Birmaher, B., Pincus, H. A., Ren, L., & Brent, D. A. (2007) · JAMA · doi:10.1001/jama.297.15.1683 · Cited by 1,086
Suicidality in Pediatric Patients Treated With Antidepressant Drugs
Hammad, T. A., Laughren, T., & Racoosin, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.332 · Cited by 1,054
Effects of psychotherapy for depression in children and adolescents: A meta-analysis
Weisz, J. R., McCarty, C. A., & Valeri, S. M. (2006) · Psychological Bulletin · doi:10.1037/0033-2909.132.1.132 · Cited by 942
(2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1132 · Cited by 752 · cited 1×
“The NIH-funded TADS study, a multisite, controlled, publicly-funded trial, explored efficacy of CBT in the short (12 weeks) and long term (9 months), compared to placebo, fluoxetine and combined fluoxetine plus CBT in 439 adolescents aged 12 – 17 years with moderate to severe depression according to the Child Depressi…”
MethodKELLER, M. B., RYAN, N. D., STROBER, M., KLEIN, R. G., KUTCHER, S. P., BIRMAHER, B., HAGINO, O. R., KOPLEWICZ, H., CARLSON, G. A., CLARKE, G. N., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200107000-00010 · Cited by 641 · cited 1×
“Paroxetine has been shown to have antidepressant activity in adolescents on some secondary measures, but not in main outcome measures [40], whereas two other studies did not demonstrate efficacy versus placebo [41,42].”
ResultCOMPTON, S. N., MARCH, J. S., BRENT, D., ALBANO, A. M., WEERSING, V. R., & CURRY, J. (2004) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000127589.57468.bf · Cited by 616
Stone, M., Laughren, T., Jones, M. L., Levenson, M., Holland, P. C., Hughes, A., Hammad, T. A., Temple, R., & Rochester, G. (2009) · BMJ · doi:10.1136/bmj.b2880 · Cited by 609 · cited 1×
“The risk is much higher when a very high suicidal ideation is present at the beginning of the treatment, or when the response to treatment is unsatisfactory [55,61].”
BackgroundA Randomized Effectiveness Trial of Interpersonal Psychotherapy forDepressed Adolescents
Mufson, L., Dorta, K. P., Wickramaratne, P., Nomura, Y., Olfson, M., & Weissman, M. M. (2004) · Archives of General Psychiatry · doi:10.1001/archpsyc.61.6.577 · Cited by 537 · cited 1×
“In these milder cases, psychotherapy is effective (62% responders versus 36% in the waiting list, according to Harrington and co-workers’ meta-analysis of 6 controlled trials), although to a lesser degree than in adults [12,14,15].”
BackgroundGoodyer, I., Dubicka, B., Wilkinson, P., Kelvin, R., Roberts, C., Byford, S., Breen, S., Ford, C., Barrett, B., Leech, A., et al. (2007) · BMJ · doi:10.1136/bmj.39224.494340.55 · Cited by 352 · cited 1×
“A different result emerges from the Adolescent Depression, Antidepressants and Psychotherapy Trial (ADAPT), which compared fluoxetine plus routine monitoring and fluoxetine plus psychotherapy in 208 depressed adolescents who did not respond to a brief psychosocial intervention [30].”
Background
Cited by
Research review: altered reward function in adolescent depression: what, when and how?
Forbes, E. E., & Dahl, R. E. (2012) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2011.02477.x · Cited by 350
“Given the evidence for involvement of the dopamine system in depression, it can appear somewhat surprising that the most effective and widely used pharmacologic treatment for depression is selective serotonin re-uptake inhibitor medications (SSRIs; Masi et al., 2010).”
Undurraga, J., & Baldessarini, R. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.306 · Cited by 269
The age-dependent effects of selective serotonin reuptake inhibitors in humans and rodents: a review
Olivier, J. D. A., Blom, T., Arentsen, T., & Homberg, J. R. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.09.013 · Cited by 131
“However, a critical issue that should be weighted in relation to pediatric SSRI exposure is that fluoxetine also exerts beneficial effects in this age group (Masi et al., 2010; Ipser et al., 2009; Lovrin, 2009).”
BackgroundFindling, R. L., Robb, A., & Bose, A. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0023 · Cited by 57
“Fluoxetine (Masi et al. 2010), the most extensively studied selective serotonin reuptake inhibitor (SSRI), has been shown to be superior to treatment with placebo in both acute (Emslie et al.”
BackgroundAntidepressants and Suicide Risk: A Comprehensive Overview
Pompili, M., Serafini, G., Innamorati, M., Ambrosi, E., Giordano, G., Girardi, P., Tatarelli, R., & Lester, D. (2010) · Pharmaceuticals · doi:10.3390/ph3092861 · Cited by 53
Metadata
- Authors
- Masi, G., Liboni, F., & Brovedani, P.
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa Healthcare
- Published
- 2010-01-27
- Volume
- 11
- Issue
- 3
- Pages
- 375-386
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W2170627025
- Cited by
- 42
- References
- 19
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacotherapy of major depressive disorder in adolescents. https://app.cochat.ai/papers/10.1517/14656560903527226
- The paper
- Masi, G., Liboni, F., & Brovedani, P. (2010). Pharmacotherapy of major depressive disorder in adolescents. Expert Opinion on Pharmacotherapy. https://doi.org/10.1517/14656560903527226
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.